Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

RARE
Ultragenyx Pharmaceutical Inc.
stock NASDAQ

Market Open
Jul 2, 2026 12:41:45 PM EDT
32.68USD+0.926%(+0.30)417,166
32.65Bid   32.76Ask   0.11Spread
Pre-market
Jul 2, 2026 9:04:30 AM EDT
32.64USD+0.803%(+0.26)1,051
After-hours
Jul 1, 2026 4:36:30 PM EDT
31.92USD-1.481%(-0.48)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
08:55AM EST  Ultragenyx Sees FY22 Crysvita Revenue In Ultragenyx Territories $250M-$260M; Sees FY22 Dojolvi Revenue $55M-$65M   Benzinga
08:54AM EST  Ultragenyx Sees FY21 Crysvita Revenue In Ultragenyx Territories Of $191M-$193M; Sees FY21 Dojolvi Revenue $38M-$40M   Benzinga
08:00AM EST  Preliminary 2021 Crysvita revenue in Ultragenyx territories of $191 million to $193 million and Dojolvi revenue of $38 million to $40 million   GlobeNewswire Inc
Jan 7, 2022
01:02PM EST  Regeneron, Ultragenxy Report Collab to Commercialize Evkeeza Outside US   Benzinga
Jan 6, 2022
04:01PM EST  Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare   GlobeNewswire Inc
Jan 5, 2022
08:09AM EST  Ultragenyx, GeneTx Provide Preliminary Update On Phase 1/2 Clinical Study Of GTX-102 In Canada And UK Patients With Angelman Syndrome   Benzinga
08:00AM EST  GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2   GlobeNewswire Inc
Jan 3, 2022
04:35PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences, Sotera Health, Eagle Pharma   Benzinga
04:12PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences   Benzinga
04:03PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights   Benzinga
04:01PM EST  Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference   GlobeNewswire Inc
Dec 1, 2021
04:34PM EST  Ultragenyx, GeneTx Report Will Participate In FAST Global Summit, Gala Dec. 4   Benzinga
04:30PM EST  GeneTx and UltragenyxAnnounce Presentations at   GlobeNewswire Inc
08:07AM EST  Ultragenyx Reports First Patient Dosed In Phase 1/2 Study Of UX053 For Treatment Of Glycogen Storage Disease Type 3   Benzinga
08:00AM EST  Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical   GlobeNewswire Inc
Nov 29, 2021
04:41PM EST  Ultragenyx to Present at Evercore 4th Annual HealthconX Conference   GlobeNewswire Inc
08:56AM EST  Ultragenyx Pharmaceutical Inc. (RARE) reported new long-term durability data from the phase 1/2 studies of DTX401 for Glycogen Storage Disease Type Ia and DTX301 for Ornithine Transcarbamylase deficiency.   RTTNews
08:24AM EST  Ultragenyx Reports Addl Positive Multi-Year Durability Data From Phase 1/2 AAV Gene Therapy Studies   RTTNews
08:06AM EST  Ultragenyx Pharmaceutical Announces Additional Multi-Year Durability Data From Phase 1/2 AAV Gene Therapy Studies   Benzinga
08:00AM EST  Ultragenyx Announces Additional Positive Multi-Year Durability   GlobeNewswire Inc
Nov 2, 2021
05:46PM EDT  Ultragenyx Pharmaceutical Q3 EPS $(1.08) Beats $(1.41) Estimate, Sales $81.65M Beat $81.55M Estimate   Benzinga
05:18PM EDT  Ultragenyx Q3 Loss/share $1.08 Vs. Loss $1.13 Year Ago   RTTNews
10:54AM EDT  The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US   Benzinga
10:41AM EDT  Earnings Scheduled For November 2, 2021   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 26, 2021
04:05PM EDT  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, November 2, 2021 at 5pm ET to discuss its financial results and corporate update for the quarter ended September 30, 2021.   GlobeNewswire Inc
Oct 25, 2021
04:05PM EDT  Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit   GlobeNewswire Inc
Oct 18, 2021
08:02AM EDT  Ultragenyx Initiates Cyprus2+, A Pivotal Clinical Trial Evaluating UX701 Gene Therapy For The Treatment Of Wilson Disease   Benzinga
08:00AM EDT  Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating   GlobeNewswire Inc
Oct 7, 2021
08:02AM EDT  GeneTx And Ultragenyx Announce First Patient Dosed In Canada In Phase 1/2 Clinical Trial Of GTX-102 In Patients With Angelman Syndrome   Benzinga
08:00AM EDT  GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman syndrome, today announced that the first patient has been dosed in the Phase 1/2 study in Canada with three other patients enrolled and scheduled to begin dosing.   GlobeNewswire Inc
Oct 4, 2021
04:05PM EDT  Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule   GlobeNewswire Inc
Oct 1, 2021
04:38PM EDT  Mereo BioPharma And Ultragenyx Present Data From Phase 2b ASTEROID Study Of UX143 (setrusumab) In Osteogenesis Imperfecta (OI) At American Society For Bone And Mineral Research (ASBMR) 2021 Annual Meeting   Benzinga
04:31PM EDT  Previously reported data demonstrated dose-dependent, statistically significant bone-building effect at multiple anatomical sites in adult patients with OI that was consistent across subtypes of OI   GlobeNewswire Inc
Sep 30, 2021
12:08PM EDT  What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical   Benzinga
11:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021   Benzinga
06:05AM EDT  HC Wainwright & Co. Initiates Coverage On Ultragenyx Pharmaceutical with Buy Rating, Announces Price Target of $106   Benzinga
Sep 27, 2021
04:31PM EDT  Ultragenyx Reports Crysvita, UX143 Data Presentations At Upcoming American Society For bone, Mineral Research 2021 Annual Meeting Oct. 1-4   Benzinga
04:30PM EDT  Ultragenyx Announces Crysvita (burosumab) and UX143   GlobeNewswire Inc
08:17AM EDT  GeneTx And Ultragenyx Announce FDA Has Removed Clinical Hold On Phase 1/2 Clinical Study Of GTX-102 For Treatment Of Angelman Syndrome In The US   Benzinga
08:00AM EDT  GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on   GlobeNewswire Inc
Sep 7, 2021
04:30PM EDT  Ultragenyx to Present at Morgan Stanley Healthcare Conference   GlobeNewswire Inc
08:08AM EDT  Ultragenyx Canada Announces Health Canada Approval Of Second Indication For Crysvita (Burosumab Injection) For Treatment Of Tumour Induced Osteomalacia In Adults   Benzinga
Sep 1, 2021
04:30PM EDT  Ultragenyx to Participate in Panel at Citis 16th   GlobeNewswire Inc
Aug 23, 2021
08:33AM EDT  Ultragenyx Announces Approval Of Dojolvi In Brazil For Long-chain Fatty Acid Oxidation Disorders In Adults And Children   RTTNews
08:32AM EDT  Ultragenyx Pharma Reports Approval Of Dojolvi In Brazil For Treatment Of Long-Chain Fatty Acid Oxidation Disorders In Adults, Children   Benzinga
08:30AM EDT  Ultragenyx Announces Approval of Dojolvi   GlobeNewswire Inc
Aug 19, 2021
11:22AM EDT  Return on Capital Employed Insights for Ultragenyx Pharmaceutical   Benzinga
10:10AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021   Benzinga
09:20AM EDT  UBS Initiates Coverage On Ultragenyx Pharmaceutical with Sell Rating, Announces Price Target of $73   Benzinga
Aug 17, 2021
04:05PM EDT  Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule   GlobeNewswire Inc
Aug 13, 2021
10:50AM EDT  Return on Capital Employed Overview: Ultragenyx Pharmaceutical   Benzinga
Aug 4, 2021
08:30AM EDT  Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow   GlobeNewswire Inc
Aug 3, 2021
10:11AM EDT  Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $91   Benzinga
08:15AM EDT  Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $141   Benzinga
Aug 2, 2021
04:31PM EDT  Ultragenyx Pharmaceutical: Q2 Earnings Insights   Benzinga
04:31PM EDT  Ultragenyx Pharmaceutical Q2 EPS $(1.81) Misses $(1.36) Estimate, Sales $86.97M Beat $85.03M Estimate   Benzinga
04:26PM EDT  Ultragenyx Pharma Q2 Loss/share $1.81 Vs. Profit $0.41 Year Ago   RTTNews
04:05PM EDT  Second quarter 2021 total revenue of $87.0 million including Crysvita1 revenue to Ultragenyx of $44.7 million   GlobeNewswire Inc
04:05AM EDT  Earnings Scheduled For August 2, 2021   Benzinga
Jul 27, 2021
05:00PM EDT  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Monday, August 2, 2021 at 5pm ET to discuss its financial results and corporate update for the quarter ended June 30, 2021.   GlobeNewswire Inc
11:13AM EDT  Ultragenyx Receives Orphan Drug Designation from FDA and European Commission for UX053, an Investigational mRNA-therapy for the Treatment of Glycogen Storage Disease Type III   Benzinga
Jul 15, 2021
07:29AM EDT  Guggenheim Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating   Benzinga
Jun 30, 2021
08:37AM EDT  Ultragenyx Appoints Corsee Sanders To Board Of Directors   RTTNews
08:30AM EDT  Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors   GlobeNewswire Inc
Jun 29, 2021
03:31PM EDT  Ultragenyx Pharmaceuticals Analyst Turns Bullish: What Investors Need To Know   Benzinga
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021   Benzinga
06:34AM EDT  B of A Securities Upgrades Ultragenyx Pharmaceutical to Buy, Announces $162 Price Target   Benzinga
Jun 10, 2021
08:49AM EDT  Ultragenyx, GeneTx Receive Approval From UK Regulatory Agency To Begin Clinical Study Of GTX-102   RTTNews
08:40AM EDT  GeneTx and Ultragenyx Receive Approval From UK MHRA To Begin Clinical Study Of GTX-102 For The Treatment Of Angelman Syndrome   Benzinga
08:30AM EDT  Patient enrollment to begin in early second half of 2021 in U.K. and Canada   GlobeNewswire Inc
Jun 3, 2021
04:01PM EDT  Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare   GlobeNewswire Inc
May 26, 2021
08:31AM EDT  Ultragenyx to Present at Jefferies Virtual Healthcare Conference   GlobeNewswire Inc
May 19, 2021
08:36AM EDT  GeneTx And Ultragenyx Receive Clearance From Health Canada To Begin Clinical Study Of GTX-102 In Canada For Treatment Of Angelman Syndrome   Benzinga
08:30AM EDT  GeneTx and Ultragenyx Receive Clearance from Health Canada to   GlobeNewswire Inc
May 18, 2021
04:05PM EDT  Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule   GlobeNewswire Inc
12:16PM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021   Benzinga
May 14, 2021
02:33PM EDT  Ultragenyx's Gene Therapies For Genetic Metabolic Disorders Show Longer-Term Durable Responses   Benzinga
08:37AM EDT  Ultragenyx Reports Positive Multi-Year Durability Data From Ongoing Phase 1/2 Gene Therapy Studies   RTTNews
08:35AM EDT  Ultragenyx Highlights Presentation Of Multi-Year Durability Data From Ongoing Phase 1/2 Gene Therapy Studies And Data On HeLa 3.0 Manufacturing Platform At American Society of Gene & Cell Therapy 2021 Annual Meeting   Benzinga
08:30AM EDT  Durable and Clinically Meaningful Responses Maintained at More than 2.5 and 3 Years Post-Treatment in Phase 1/2 Studies of DTX401 for GSDIa and DTX301 for OTC   GlobeNewswire Inc
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 10, 2021
04:01PM EDT  Ultragenyx to Present at Bank of America Securities Healthcare   GlobeNewswire Inc
May 6, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021   Benzinga
08:01AM EDT  10 Biggest Price Target Changes For Thursday   Benzinga
06:38AM EDT  Citigroup Upgrades Ultragenyx Pharmaceutical to Buy, Lowers Price Target to $151   Benzinga
06:23AM EDT  Evercore ISI Group Upgrades Ultragenyx Pharmaceutical to Outperform, Announces $144 Price Target   Benzinga
May 5, 2021
08:42AM EDT  Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $156   Benzinga
May 4, 2021
04:15PM EDT  Ultragenyx Pharmaceutical Reaffirms FY21 Guidance   Benzinga
04:15PM EDT  Ultragenyx Pharmaceutical Q1 EPS $(2.03) Misses $(1.24) Estimate, Sales $99.40M Beat $77.04M Estimate   Benzinga
04:01PM EDT  First quarter 2021 total revenue of $99.4 million and Crysvita1 revenue to Ultragenyx of $42.1 million   GlobeNewswire Inc
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
Apr 28, 2021
04:01PM EDT  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., will present at the 7th Annual Truist Securities Life Sciences Summit on Wednesday, May 5, 2021 at 1:00 PM ET.   GlobeNewswire Inc
08:31AM EDT  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, May 4, 2021 at 5pm ET to discuss its financial results and corporate update for the first quarter ended March 31, 2021.   GlobeNewswire Inc
Apr 22, 2021
08:32AM EDT  Ultragenyx Completes End-of-Phase 2 Meeting With FDA And Finalizes Phase 3 Study Design For DTX301 Ornithine Transcarbamylase Gene Therapy Program   Benzinga
08:30AM EDT  Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA   GlobeNewswire Inc
Apr 19, 2021
11:05AM EDT  Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $170   Benzinga
Apr 5, 2021
08:01AM EDT  n-Lorem Foundation Partners With Ultragenyx To Bolster Development Of Personalized Medicines For Patients With Ultra-Rare Diseases   Benzinga
Mar 8, 2021
08:47AM EST  Ultragenyx Announces FDA Clearance Of IND Application For UX053   RTTNews
08:47AM EST  Ultragenyx Announces FDA Clearance of Investigational New Drug   GlobeNewswire Inc
08:36AM EST  Ultragenyx Announces FDA Clearance Of Investigational New Drug Application For UX053, An mRNA For Treatment Of Glycogen Storage Disease Type III   Benzinga
Mar 3, 2021
08:31AM EST  Ultragenyx to Present at Barclays Global Healthcare Conference   GlobeNewswire Inc
Feb 17, 2021
04:01PM EST  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the following upcoming investor conferences:   GlobeNewswire Inc
10:44AM EST  Ultragenyx's Dojolvi Ok'd In Canada For Genetic Metabolic Disorder   Benzinga
08:36AM EST  Ultragenyx Announces Health Canada Approval Of Dojolvi For The Treatment Of Long-Chain Fatty Acid Oxidation Disorders In Adults And Children   Benzinga
08:30AM EST  Ultragenyx Announces Approval of Dojolvi   GlobeNewswire Inc
Feb 16, 2021
04:53AM EST  SVB Leerink Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $178   Benzinga
Feb 12, 2021
10:59AM EST  Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $186   Benzinga
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 12, 2021   Benzinga
09:04AM EST  Piper Sandler Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $170   Benzinga
06:22AM EST  JP Morgan Downgrades Ultragenyx Pharmaceutical to Neutral, Announces $165 Price Target   Benzinga
Feb 11, 2021
05:20PM EST  Ultragenyx Pharmaceutical Inc. (RARE) Thursday reported fourth-quarter loss of $24.0 million or $0.37 per share, wider than last year' loss of $93.8 million or $1.62 per share.   RTTNews
04:25PM EST  Recap: Ultragenyx Pharmaceutical Q4 Earnings   Benzinga
04:16PM EST  Ultragenyx Pharmaceutical Q4 EPS $(0.37) Beats $(1.16) Estimate, Sales $91.54M Beat $70.54M Estimate   Benzinga
04:16PM EST  Ultragenyx Pharma Q4 Loss/share $0.37 Vs. Loss $1.62 Year Ago   RTTNews
04:05PM EST  2020 total revenue of $271.0 million and 2020 Crysvita1 revenue to Ultragenyx of $138.9 million   GlobeNewswire Inc
03:51AM EST  Earnings Scheduled For February 11, 2021   Benzinga
Feb 6, 2021
12:42PM EST  The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight   Benzinga
Feb 4, 2021
08:31AM EST  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, February 11, 2021 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2020.   GlobeNewswire Inc
Jan 21, 2021
08:36AM EST  Ultragenyx Reports FDA Clearance For Investigational New Drug Application For UX701, New Gene Therapy For Treatment Of Wilson Disease   Benzinga
08:30AM EST  Ultragenyx Announces FDA Clearance of Investigational New Drug   GlobeNewswire Inc
Jan 11, 2021
07:04AM EST  Ultragenyx Pharma Provides Crysvita Sales Guidance Updates   Benzinga
07:00AM EST  Preliminary 2020 Crysvita revenue in Ultragenyx Territories of $137 million to $139 million   GlobeNewswire Inc
Jan 8, 2021
09:28AM EST  Ultragenyx Reports Positive Longer-term Data From Phase   RTTNews
09:06AM EST  Ultragenyx: Durable Response Reported From Phase 1/2 Studies Of DTX401 For GSDIa And DTX301 For OTC   RTTNews
09:03AM EST  Ultragenyx Highlights 'Progress Across Broad Gene Therapy Portfolio' And Announces Longer-Term Data From Multiple Phase 1/2 Gene Therapy Studies   Benzinga
09:00AM EST  Durable and Clinically Meaningful Responses Reported from Phase 1/2 Studies of DTX401 for GSDIa and DTX301 for OTC   GlobeNewswire Inc
Jan 5, 2021
08:31AM EST  Ultragenyx to Present at 39th Annual J.P. Morgan Virtual   GlobeNewswire Inc
Dec 26, 2020
09:16AM EST  The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks   Benzinga
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 18, 2020
10:24AM EST  Shares of Mereo BioPharma Group plc (MREO) are currently surging over 50% after the clinical stage biopharmaceutical company announced a collaboration deal with Ultragenyx Pharmaceutical Inc. (RARE), a company focused on development of treatment for ultra-rare diseases.   RTTNews
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 17, 2020
04:07PM EST  Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta; Mereo Will Receives $50M Upfront And Is Eligible For Milestones Up To $254M   Benzinga
04:05PM EST  Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyxs existing bone franchise   GlobeNewswire Inc
08:10AM EST  The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut   Benzinga
Dec 16, 2020
01:16PM EST  Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $175   Benzinga
07:15AM EST  The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Dec 9, 2020
04:07PM EST  Ultragenyx Announces Orphan Drug Designation For UX701 For Treatment Of Wilson Disease   Benzinga
04:05PM EST  Ultragenyx Announces Orphan Drug Designation for UX701 for the   GlobeNewswire Inc
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 7, 2020
04:21PM EST  FDA Site Shows Orphan Drug Designation Of Ultragenyx Adeno-Associated Viral Vector Serotype 9 Encoding Human ATP7B For Treatment Of Wilson's Disease   Benzinga
03:36PM EST  Ultragenyx Pharmaceutical shares were trading lower after Wedbush downgraded the stock from Outperform to Neutral.   Benzinga
11:03AM EST  Wedbush Downgrades Ultragenyx Pharmaceutical to Neutral, Raises Price Target to $110   Benzinga
Dec 5, 2020
01:03PM EST  GeneTx and Ultragenyx Announced Presentation of Phase 1/2 Data on Investigational GTX-102 in Patients with Angelman Syndrome; Additional Data, Including Eeg Findings, Support Prior Initial Indications of Activity and There Were No New Adverse Events   Benzinga
01:00PM EST  Results presented at Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit   GlobeNewswire Inc
Dec 4, 2020
08:04AM EST  The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs   Benzinga
Nov 24, 2020
09:13AM EST  Evercore ISI Group Reinstates In-Line on Ultragenyx Pharmaceutical, Announces $110 Price Target   Benzinga
08:38AM EST  Ultragenyx To Present At Upcoming Healthcare Conferences On Dec. 1 And 2   Benzinga
08:31AM EST  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the following upcoming investor conferences:   GlobeNewswire Inc
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 12, 2020
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 9, 2020
08:12AM EST  Ultragenyx Announces Plans To Build Large-Scale Gene Therapy Manufacturing Facility To Support Pipeline Of Therapies For Rare Diseases   Benzinga
08:05AM EST  Ultragenyx Announces Plans to Build Large-scale Gene Therapy   GlobeNewswire Inc
Nov 6, 2020
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
Nov 5, 2020
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
Nov 4, 2020
08:21AM EST  The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings   Benzinga
Nov 2, 2020
11:21AM EST  Ultragenyx Announces Closing of Public Offering of Common Stock   GlobeNewswire Inc
Oct 29, 2020
08:26AM EDT  Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $105   Benzinga
07:30AM EDT  The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal   Benzinga
Oct 28, 2020
11:55AM EDT  Utlragenyx Pharmaceutical shares are trading lower after the company announced a $400 million share common stock offering.   Benzinga
08:17AM EDT  Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $91   Benzinga
07:49AM EDT  Ultragenyx Announces Proposed Offering Of $400M Shares Of Common Stock   Benzinga
07:47AM EDT  Ultragenyx Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
04:58AM EDT  SVB Leerink Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $115   Benzinga
Oct 27, 2020
10:29PM EDT  Ultragenyx Pharmaceutical Inc. (RARE) reported that its third-quarter net loss narrowed to $68.8 million or $1.13 per share, from $113.0 million or $1.96 per share last year.   RTTNews
05:00PM EDT  Recap: Ultragenyx Pharmaceutical Q3 Earnings   Benzinga
04:21PM EDT  Ultragenyx Q3 Net Loss $68.8 Mln Or $1.13/Shr Vs Loss $113.0 Mln Or $1.96/Shr Last Year   RTTNews
04:10PM EDT  Ultragenyx Pharmaceutical Raises The Lower End Of ITs FY20 Crysvita Sales From $125M To $130M   Benzinga
04:08PM EDT  Ultragenyx Pharmaceutical Q3 EPS $(1.13) Beats $(1.27) Estimate, Sales $81.47M Beat $53.89M Estimate   Benzinga
04:05PM EDT  Third quarter 2020 total revenue of $81.5 million and Crysvita1revenue of $37.3 million   GlobeNewswire Inc
08:25AM EDT  The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings   Benzinga
04:18AM EDT  Earnings Scheduled For October 27, 2020   Benzinga
Oct 26, 2020
04:04PM EDT  UPDATE: GeneTx And Ultragenyx Announce Highest Doses Associated With A Significant But Reversible Safety Issue   Benzinga
04:04PM EDT  GeneTx And Ultragenyx Announce Interim Phase 1/2 Data On Investigational GTX-102 Demonstrating Improvement In Patients With Angelman Syndrome; Efficacy In Multiple Functional Measures Observed In All Five Patients Treated   Benzinga
04:01PM EDT  Efficacy in multiple functional measures observed in all five patients treated   GlobeNewswire Inc
Oct 23, 2020
08:04AM EDT  Ultragenyx And Solid Biosciences Announce Strategic Collaboration To Develop And Commercialize New Gene Therapies For Duchenne Muscular Dystrophy; Solid To Receive $40M Upfront Via Equity Investment And Up To $255M In Milestones Plus Royalty Payments   Benzinga
08:00AM EDT  -Collaboration combines Solids differentiated microdystrophin construct and Ultragenyxs HeLa PCL manufacturing platform for use with AAV8 and variants-   GlobeNewswire Inc
Oct 21, 2020
08:31AM EDT  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, October 27, 2020 at 5pm ET to discuss third quarter 2020 financial results and provide a corporate update.   GlobeNewswire Inc
Oct 15, 2020
11:15AM EDT  B of A Securities Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $107   Benzinga
Oct 13, 2020
10:26AM EDT  Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $89   Benzinga
Sep 25, 2020
08:05AM EDT  Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit   GlobeNewswire Inc
Sep 3, 2020
08:31AM EDT  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the following upcoming investor conferences:   GlobeNewswire Inc
Sep 2, 2020
08:15AM EDT  Ultragenyx Appoints Mardi Dier As CFO   RTTNews
08:01AM EDT  Ultragenyx Appoints Mardi C. Dier as Chief Financial Officer   GlobeNewswire Inc
Sep 1, 2020
08:38AM EDT  Ultragenyx Appoints Ernie Meyer As EVP And Chief Human Resources Officer   RTTNews
08:31AM EDT  Ultragenyx Expands Leadership Team and Appoints Ernie Meyer as   GlobeNewswire Inc
Aug 26, 2020
10:51AM EDT  Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $92   Benzinga
Aug 4, 2020
08:31AM EDT  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will hold virtual presentations at the following upcoming investor conferences:   GlobeNewswire Inc
Jul 31, 2020
09:34AM EDT  Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $87   Benzinga
Jul 30, 2020
05:13PM EDT  Ultragenyx Pharma Q2 EPS $0.41 Vs. Loss $1.72 Year Ago   RTTNews
04:05PM EDT  Ultragenyx Reaffirms FY20 Guidance   Benzinga
04:05PM EDT  Ultragenyx Pharmaceutical Q2 EPS $0.41 Up From $(1.72) YoY, Sales $61.70M Up From $24.15M YoY   Benzinga
04:06AM EDT  Earnings Scheduled For July 30, 2020   Benzinga
Jul 29, 2020
07:55AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Wed., Jul. 29, 2020: F, KODK, MRNA, RARE, QCOM   Benzinga
Jul 24, 2020
08:35AM EDT  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, July 30, 2020 at 5pm ET to discuss second quarter 2020 financial results and provide a corporate update.   GlobeNewswire Inc
Jul 22, 2020
08:41AM EDT  Ultragenyx Announces U.S. Commercial Launch Of Dojolvi For The Treatment Of Long-chain Fatty Acid Oxidation Disorders   RTTNews
08:35AM EDT  Ultragenyx Announces U.S. Commercial Launch of   GlobeNewswire Inc
Jul 15, 2020
11:01AM EDT  Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $88   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC